Navigation Links
Oculus Innovative Sciences Microcyn Technology Presented in Poster,at European Wound Management Association Conference

PETALUMA, Calif.--(BUSINESS WIRE)--May 14, 2007 - Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) today reported that its Microcyn Technology was the subject of a poster presentation at the European Wound Management Association (EWMA) conference that was held in Glasgow, Scotland this past week.

The poster, entitled Clinical Results About an Antimicrobial Solution in the Treatment of Infected Chronic Wounds, utilized Cutting & Harding infection criteria to evaluate the performance of the Microcyn Technology plus antibiotics versus a control group of povidone iodine plus antibiotics. Forty patients with infected wounds were randomized into the two groups; 20 each in the Microcyn and povidone iodine groups. Analyzed data included: pain (VAS), improvement/resolution of the clinical signs of infection, bad odour reduction, white blood cells count and duration of hospitalization.

The study, led by investigators E. Ricci, S. Astolfi and R. Cassino of the operative unit of vulnology at the San Luca Clinic in Turin, Italy, concluded that the Microcyn Technology showed better results than did the povidone iodine group in reduced number of days of hospitalization, reduction of clinical signs of infection and pain reduction.

Dr. Andres Gutierrez, director of medical affairs for Oculus Innovative Sciences, said, "This poster, along with the dozen other international clinical studies conducted to date, further supports the use of Microcyn Technology in the treatment of infected wounds. Encouraged by these data, we have initiated several study sites for the FDA Phase II trial in the treatment of mildly infected diabetic foot ulcers in the United States."

Microcyn Technology, with three 510k FDA clearances in the United States for cleaning, moistening, lubricating and debriding wounds, is not approved in the U.S. for treatment of infection.

About Oculus

Oculus Innovative Sciences is a bio pharmaceutical company that develops, manufactures and markets a family of Microcyn(R) Technology-based products intended to help prevent and treat infections in chronic and acute wounds. Oculus' platform technology, called Microcyn, is a non-irritating oxychlorine compound designed to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria, viruses, fungi and spores.

Oculus' principal operations are in Petaluma, California, and it conducts operations in Europe and Latin America through its wholly-owned subsidiaries, Oculus Innovative Sciences Netherlands B.V. and Oculus Technologies of Mexico, S.A. de C.V. Our website is www.oculusis.com.

Forward-Looking Statements

Except for historical information herein, the matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are identified by the use of words such as "intended," "reduce," "reduction," and "designed," among others. These forward-looking statements are based on Oculus Innovative Sciences, Inc.'s current expectations. Investors are cautioned that such forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company's business including risks inherent in the development and commercialization of potential products, the risk that scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, the Company's future capital needs, and its ability to obtain additional funding and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission including the quarterly report on Form 10-Q for the quarter ended December 31, 2006. Oculus Innovative Sciences disclaims any obligation to update these forward-looking statements.

Oculus and Microcyn are trademarks or regis tered trademarks of Oculus Innovative Sciences, Inc.

Contact

Oculus Innovative Sciences, Inc.
Director of Public and Investor Relations
Dan McFadden, 425-753-2105
dmcfadden@oculusis.com
or
The Ruth Group
Investors:
Sara Ephraim, 646-536-7002
sephraim@theruthgroup.com
or
Media:
Jason Rando / Janine McCargo, 646-536-7025 / 7033
jrando@theruthgroup.com
jmccargo@theruthgroup.com


'"/>




Related medicine technology :

1. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
2. Innovative Cancer Drug MabThera Again Shown To Improve Survival Rates In Patients With Lymphoma
3. DNA Therapeutics Reports a Novel Mechanism of Action and a Biomarker of its Lead Molecule Dbait That Open an Innovative Pathway-Targeting in Molecular Cancer Therapy
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
6. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
7. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
8. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
9. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
10. Answerthink and LORENZ Life Sciences Group Announce Strategic Alliance for the SAP Life Science Industry
11. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology:
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
Breaking Medicine News(10 mins):